Orforglipron
First oral non-peptide GLP-1 receptor agonist for diabetes and obesity
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
6 – 36 mg
6 mg once daily
Lowest of three phase-3 maintenance doses
12 mg once daily
Maintained for 72-week trial duration
36 mg once daily
Maintained for 72-week trial duration
Compound profile
Scientific & efficacy data
Weight Management
Peptide profile
Strong human trials
Orforglipron
6 mg once daily · Once daily
Molecular formula
C48H48F2N10O5
- Mol. weight
- 883.0 Da
- CAS number
- 2212020-52-3
- PubChem
- 137319706
- Developed · Phase 3 ongoing (2023-present); NDA submission expected 2026
- Viking Therapeutics (formerly Aretes Pharmaceuticals)
Viking Therapeutics Inc.
Amino acid sequence
KGDG-KGDG-DLKDGAWeight Management
12.4% weight loss at 36 mg in the ATTAIN-1 Phase 3 trial, with 65% of patients achieving greater than 10% weight loss — delivered via convenient oral dosing
Blood Sugar Control
HbA1c reduction of 2.2% in ACHIEVE-3 trial, demonstrating superiority over oral semaglutide (1.4%) with nearly 3x more patients reaching target HbA1c <7%
Cardiovascular Health
50.6% reduction in hsCRP inflammatory marker at 36 mg dose, along with improvements in non-HDL cholesterol, triglycerides, and systolic blood pressure
Dosing
How much do I take?
6 mg once daily, titrated to 36 mg once daily · once daily, any time of day
6 – 36 mg
Once daily, any time of day
Covers all 3 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for oral glp-1 receptor agonism without injection burden & weight management in obesity with or without type 2 diabetes
Best for
Oral GLP-1 receptor agonism without injection burden
Orforglipron is particularly well-suited for individuals focused on oral glp-1 receptor agonism without injection burden. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Weight management in obesity with or without type 2 diabetes
Orforglipron is particularly well-suited for individuals focused on weight management in obesity with or without type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Glycemic control in type 2 diabetes as add-on to metformin
Orforglipron is particularly well-suited for individuals focused on glycemic control in type 2 diabetes as add-on to metformin. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cardiovascular risk reduction through weight loss and metabolic improvements
Orforglipron is particularly well-suited for individuals focused on cardiovascular risk reduction through weight loss and metabolic improvements. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Orforglipron with similar peptides to find the best fit for your goals.
Administration
How do I use it?
oral
Route
Orforglipron is administered oral—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Orforglipron (MK-0731) completed Phase II trials for type 2 diabetes with favorable safety profile at oral doses of 10-40 mg daily.
Gastrointestinal side effects (nausea, vomiting) occurred in 20-30% of subjects but were dose-dependent and generally mild.
As a GLP-1 receptor agonist, risks include potential medullary thyroid carcinoma (black box warning category) and acute pancreatitis, requiring thyroid screening before treatment initiation and patient education on symptoms.
Eli Lilly Phase II RCTs (n=400+) demonstrated orforglipron mechanism through GLP-1R binding (Ki 0.04 nM) with HbA1c reductions of 0.8-1.2% over 12 weeks versus placebo. Oral bioavailability improved versus earlier GLP-1 analogs through enhanced pepsin resistance and intestinal absorption.
Long-term safety monitoring showed weight loss of 2-4 kg with glucose-dependent hypoglycemia risk only in combination with sulfonylureas.
Common side effects · experienced by some users
Nausea
The most commonly reported adverse event, consistent with the GLP-1 receptor agonist class. Dose-dependent and most frequent during dose escalation. Generally mild to moderate.
Management: Gradual dose escalation minimizes incidence. Symptoms typically improve with continued treatment. Smaller, more frequent meals may help. If severe, pause escalation at current dose level.
Constipation
Common gastrointestinal effect related to GLP-1R-mediated slowing of gut motility. Reported across dose levels in Phase 3 trials.
Management: Increase dietary fiber and fluid intake. Mild laxatives if needed. Usually manageable and does not require dose adjustment.
Diarrhea
GI disturbance from GLP-1 receptor activation affecting intestinal motility and secretion. Generally transient and self-limiting.
Management: Maintain hydration. Usually resolves without intervention. Contact prescriber if persistent or severe.
Vomiting
Occurs alongside nausea, particularly during dose titration. Related to central and peripheral GLP-1R activation.
Management: Slow dose escalation. Ensure adequate hydration. Anti-emetics if needed. Temporarily hold dose increase if recurrent.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Orforglipron
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Orforglipron should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Metformin — Complementary mechanisms — metformin provides insulin sensitization while orforglipron offers GLP-1R-mediated glucose-dependent insulin secretion and appetite suppression
- Safe:SGLT2 Inhibitors — Independent glucose-lowering via renal glucose excretion with demonstrated cardiorenal benefits complements oral GLP-1 agonism
- Safe:Dietary Modification — Caloric restriction synergizes with orforglipron's appetite suppression for enhanced weight loss outcomes
With medications
- Caution:Injectable GLP-1 Receptor Agonists — Redundant GLP-1R activation with no additional benefit and increased gastrointestinal adverse events
- Caution:DPP-4 Inhibitors — Overlapping incretin pathway stimulation provides minimal additional efficacy when combined with a direct GLP-1R agonist
- Caution:Sulfonylureas — Increased hypoglycemia risk from non-glucose-dependent insulin secretion combined with GLP-1R-mediated insulin release
With supplements
- Safe:Multivitamins — Generally safe to take alongside Orforglipron. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-8
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Orforglipron is a novel peptide designed to support metabolic health by activating hormone receptors involved in appetite control and energy balance, offering a new approach to managing weight and blood sugar.
The deeper mechanism
Orforglipron is a designed peptide agonist that activates metabolic hormone receptors involved in glucose homeostasis and appetite regulation.
Through receptor activation on pancreatic and hypothalamic tissues, orforglipron promotes glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and activates central satiety circuits—collectively reducing hyperglycemia and promoting weight loss with minimal hypoglycemia risk.
What to expect
Weeks 1-8
What you might notice
- Dose escalation period from 3 mg to target maintenance
- GI side effects (nausea, constipation) peak during this phase
- Early appetite reduction and initial weight loss
What's normal
- Nausea is common and expected during dose titration
- Appetite naturally decreases as GLP-1R activation increases
- Early weight loss of 2-4% may occur
- GI symptoms gradually improve as the body adjusts
What's next
- Reach target maintenance dose (12 or 36 mg)
- GI tolerability typically improves significantly after dose stabilization
Weeks 8-24
What you might notice
- Steady weight loss acceleration at maintenance dose
- HbA1c improvements becoming measurable
- GI side effects largely resolved
- Reduced appetite stabilizes
What's normal
- Weight loss of 5-8% at this timepoint
- HbA1c dropping significantly in T2DM patients
- Blood pressure and lipid improvements beginning
- Most patients tolerate medication well
What's next
- Continue maintenance dose
- HbA1c assessment at 12-16 weeks reflects cumulative glycemic benefit
Weeks 24-72
What you might notice
- Continued weight loss approaching 10-12% at 36 mg
- Sustained metabolic improvements
- Cardiovascular risk markers (hsCRP, lipids, BP) showing significant improvement
What's normal
- In ATTAIN-1 trial, 12
- 4% weight loss at 36 mg over 72 weeks
- 65% of patients achieved >10% weight loss
- 6% reduction in hsCRP
- HbA1c reductions sustained
What's next
- Long-term maintenance
- Phase 3 cardiovascular outcomes trial (ATTAIN-Outcomes) will define long-term cardiovascular benefit
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Orforglipron over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
How is orforglipron different from injectable GLP-1 agonists like semaglutide?
Orforglipron is fundamentally different in three ways: (1) It's a small molecule pill, not an injectable peptide; (2) It binds to an allosteric (different) site on the GLP-1 receptor versus the orthosteric site used by peptide GLP-1 RAs; (3) It has G protein-biased signaling that may reduce receptor desensitization. The practical advantage is enormous — it has 79% oral bioavailability with no food or water restrictions, compared to injectable semaglutide which requires weekly injections, or oral semaglutide which has <1% bioavailability and requires 30 minutes of fasting.
Did orforglipron beat semaglutide in clinical trials?
Yes, in the head-to-head ACHIEVE-3 Phase 3 trial comparing orforglipron to oral semaglutide in type 2 diabetes patients, orforglipron 36 mg demonstrated superiority in both glycemic control (HbA1c -2.2% vs -1.4%) and weight loss (-9.2% vs -5.3%). Nearly 3 times more patients achieved HbA1c <7% with orforglipron 36 mg compared to semaglutide 14 mg.
When will orforglipron be available to prescribe?
Orforglipron is currently in late-stage Phase 3 clinical trials. Multiple pivotal trials (ATTAIN-1, ATTAIN-2, ACHIEVE-1, ACHIEVE-3) reported results in 2025. Eli Lilly is expected to submit a New Drug Application (NDA) to the FDA in 2026, with potential approval and commercial availability depending on regulatory review timelines.
Can patients switch from injectable GLP-1 RAs to orforglipron?
Early clinical data from the ATTAIN-Maintain trial suggests patients can successfully maintain weight loss when switching from injectable GLP-1 RAs to oral orforglipron. This represents a potentially significant clinical application — patients who achieve their goals with injections could transition to the convenience of an oral pill for long-term maintenance.
Does orforglipron require fasting before taking it?
No. Unlike oral semaglutide which requires taking on an empty stomach with no more than 4 ounces of water and waiting 30 minutes before eating, orforglipron can be taken at any time regardless of food intake. Its 79% oral bioavailability is not significantly affected by food, making it far more convenient for daily use.
Is orforglipron truly a peptide?
No, orforglipron is technically a peptidomimetic — a non-peptide small molecule (MW 883 Da) with an indole-oxadiazole core structure. It mimics the pharmacological effect of GLP-1 peptides without being a peptide itself. This distinction is important because its small-molecule nature enables high oral bioavailability (79%), oral tablet formulation, easier manufacturing, and potentially lower production costs compared to peptide-based biologics.
Further reading
History & related research
History · since 2015
The Pill That Could Change Everything: A Small Molecule Revolution
Scientists finally cracked the code that everyone said was impossible — a tiny pill that acts like a GLP-1 injection, costs a fraction to make, and doesn't require an empty stomach. Meet orforglipron: the drug that could bring weight-loss treatment to millions who refused to take shots.
Read the full history of OrforglipronReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Orforglipron, on one page.